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ABSTRACT 
Statins are drugs that competitively inhibit the enzyme 3-hydroxy-3-
methylglutaryl coenzyme A reductase (HMG-CoA). Besides their important lipid-
lowering action, they also are pleiotropic agents. Several studies have explored a 
possible protective effect of statins to reduce the morbidity and mortality of various 
infectious diseases. The antimicrobial activity of statins has been reported by in 
vivo and in vitro studies. The aim of this study was to evaluate the effects of statins 
on the growth, viability and biofilm formation of pathogenic aerobic bacteria. The 
Minimum Inhibitory Concentrations (MIC) of atorvastatin, pravastatin and 
simvastatin against planktonic cells  of Staphylococcus aureus, Pseudomonas 
aeruginosa, Escherichia coli and Enterococcus faecalis strains were obtained. 
Since simvastatin showed activity against S. aureus, its effects on cell viability 
were evaluated in a time-kill and post-antibiotic effect (PAE) assays. A possible 
synergistic effect between simvastatin and vancomycin was also assessed. In 
addition, the effect of simvastatin against biofilms of S. aureus was tested. The 
MIC values of simvastatin for S. aureus were: 15.65 µg/ml (ATCC 29213) and 
31.25 µg/ml (ATCC 33591, 43300, 14458 and 6538). The effect showed by 
simvastatin was dose-dependent, with a bactericidal effect at 4x > MIC 
concentrations and a bacteriostatic effect at MIC concentration. No synergistic 
effect was found between simvastatin and vancomycin. Simvastatin was able to 
reduce the formation of biofilms in concentrations ranging from 1/8MIC to 4xMIC. In 
addition, the 4xMIC was able to decrease the viability, biomass and production of 
extracellular polysaccharides and increase the production of intracellular 
polysaccharides on mature biofilm of S. aureus. The protein production on biofilm 
was not altered in the presence of simvastatin . In conclusion, our results showed 
that simvastatin has a great potential to be explored, especially in relation to the 
development new antimicrobial agents. 
Key-words: Statins. Staphylococcus aureus. Biofilms. 
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RESUMO 
As estatinas são um grupo de fármacos que atuam como inibidores 
competitivos da enzima 3-Hidroxi-3-MetilGlutaril Coenzima-A Redutase (HMG-CoA 
redutase). Além de importantes agentes hipolipemiantes, também apresentam 
outros efeitos, chamados de pleiotrópicos. Diversos estudos têm explorado um 
possível efeito protetor das estatinas atuando na redução na morbidade e 
mortalidade de várias doenças infecciosas. A atividade antimicrobiana das 
estatinas tem sido reportada por estudos in vivo e in vitro. O objetivo desse estudo 
foi avaliar os efeitos das estatinas sobre o crescimento e viabilidade de bactérias 
aeróbias patogênicas, e o efeito da sinvastatina sobre o biofilme de 
Staphylococcus aureus. Culturas das espécies de Staphylococcus aureus, 
Pseudomonas aeruginosa, Escherichia coli e Enterococcus faecalis foram 
avaliadas na forma planctônica quanto à sensibilidade à atorvastatina, 
pravastatina e sinvastatina, através do teste de Concentração Inibitória Mínima 
(CIM). Além disso, diante da atividade apresentada pela sinvastatina contra S. 
aureus, foi determinada a ação desse  fármacosobre a viabilidade celular através 
dos testes de Time-kill e Efeito pós-antibiótico (EPA). Também foi verificado um 
possível efeito sinérgico entre a sinvastatina e vancomicina. Por fim, a ação da 
sinvastatina foi avaliada contra biofilmes de S. aureus. Os valores de CIM da 
sinvastatina para o microrganismo S. aureus foram: 15,65 µg/ml (ATCC 29213) e 
31,25 µg/ml (ATCC 33591, 43300, 14458 e 6538). O efeito apresentado pela 
sinvastatina foi dose-dependente, sendo de caráter bactericida para 
concentrações 4x > MIC e bacteriostático para a concentração igual ao MIC. Não 
foi encontrado nenhum tipo de interação entre a associação de sinvastatina e 
vancomicina. Entretanto, a sinvastatina foi capaz de reduzir a formação do biofilme 
nas concentrações entre 1/8CIM à 4xCIM. Além disso, na concentração 4xMIC foi 
capaz de diminuir a viabilidade, biomassa e a produção de polissacarídeos 
extracelulares e aumentar a produção de polissacarídeos intracelulares de 
biofilmes maduros de S. aureus. A produção de proteínas pelo biofilme não foi 
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alterada. Em conclusão, os resultados encontrados mostram que a sinvastatina 
possui um grande potencial a ser explorado, principalmente em relação ao 
descobrimento de novos antimicrobianos. 
Palavras-chave: Estatinas. Staphylococcus aureus. Biofilmes. 
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INTRODUÇÃO 
 
As estatinas são os agentes hipolipemiantes mais utilizado para a 
redução de lipídios em pacientes com níveis elevados de colesterol. Esse grupo 
de medicamentos apresenta boa margem de segurança e tolerância durante 
utilização prolongada, com baixa frequência de efeitos colaterais (Maron et al., 
2000; Wilt et al., 2004).  
As primeiras estatinas descobertas foram a mevastatina e lovastatina, 
tendo sido isoladas a partir de culturas de Penicillium citrinum e Aspergillus terreus 
(Alberts et al., 1980). Com o intuito de aprimorar o tratamento das dislipidemias, 
novas estatinas surgiram a partir de modificações químicas da lovastatina, dando 
origem a sinvastatina e a pravastatina. Outras estatinas consideradas totalmente 
sintéticas também surgiram, como é o caso da fluvastatina, atorvastatina, 
rosuvastatina, cerivastatina e pitavastatina (Maron et al., 2000; Mason et al., 2005; 
Sirtori, 2014). Apesar das diferenças nas propriedades físico-químicas entre as 
estatinas, todas agem através do mesmo mecanismo de ação, comportando-se 
como inibidores competitivos da enzima 3-Hidroxi-3-MetilGlutaril Coenzima-A 
Redutase (HMG-CoA redutase) (Sirtori, 2014). 
Desse modo, além da capacidade de reduzir o colesterol, as estatinas 
apresentam outros efeitos que não podem ser associados apenas às reduções 
lipídicas, os chamados efeitos não-lipídeo-relacionados ou efeitos pleitrópicos 
(Liao & Laufs, 2005). Efeitos antioxidantes, ação anticarcinogênica através da 
inibição da proliferação celular, estabilização de placas ateroscleróticas, efeitos 
anticoagulantes, melhorias na disfunção endotelial mediada por óxido nitroso, 
inibição da rejeição de enxertos após transplante de coração e rim, ação no tecido 
ósseo, efeitos anti-inflamatórios e imunomoduladores, são alguns exemplos de 
efeitos pleitrópicos proporcionados pelas estatinas (Davignon & Laaksonem, 1999; 
Bellosta et al., 2000; Blanco-Colio et al., 2003; Liao & Laufs, 2005). 
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O potencial dessas drogas no controle de respostas infeciosas tem sido 
bastante explorado (Almog et al., 2006; Gao et al., 2008; Kopterides & Falagas, 
2009; Tleyjeh et al., 2009;  Janda et al., 2010; Ajroucheet al., 2013; López-Cortés 
et al., 2013). Esses estudos investigam um possível efeito protetor das estatinas, 
atuando na redução na morbidade e mortalidade de várias doenças infecciosas. A 
maioria dos estudos aponta uma redução nas taxas de mortalidade associadas à 
sepse e bacteremias entre os pacientes que fazem uso das estatinas para a 
redução de colesterol (Tleyjeh et al., 2009; Janda et al., 2010; Ajroucheet al., 
2013; López-Cortés et al., 2013). Entretanto, outros estudos demonstram ausência 
desse efeito protetor (Wan et al., 2014). Diversos mecanismos que poderiam 
explicar esse efeito das estatinas na proteção de respostas infecciosas foram 
propostos, inclusive um efeito antibacteriano (Jerwood & Cohen, 2008; Janda et 
al., 2010). 
A atividade antibacteriana apresentada pelas estatinas tem sido 
investigada por estudos in vitro e in vivo (Rego et al. 2007; Horn et al., 2008; 
Jerwood & Cohen, 2008; Bergman et al., 2011; Masadeh et al., 2012). A 
sinvastatina se mostrou eficaz contra diversos patógenos como, por exemplo, 
Streptococcus pneumoniae, Haemophilus influenzae, Moraxella catarrhalis 
(Bergman et al., 2011), Escherichia coli, Pseudomonas aeruginosa, dentre outros 
(Masadeh et al., 2012)  Além de apresentar atividade contra Staphylococcus 
aureus, esse fármaco também foi capaz de inibir a invasão celular por esse 
microrganismo (Horn et al., 2008). Outras estatinas também apresentaram 
atividade in vitro (Masadeh et a., 2012). 
Staphylococcus aureus é o principal patógeno associado às 
bacteremias, representando 40% dos casos. Dentre as cepas mais comumentes 
associadas a esse tipo de infecção, temos S. aureus meticilina-resistente (MRSA) 
e S. aureus oxacilina-resistente (SARO). Outros patógenos que também 
apresentam alta associação com as bacteremias são: Pseudomonas aeruginosa, 
S. epidermides, Enterobacter spp, Escherichia coli, Klebsiella spp e Acinetobacter 
spp (Lark et al., 2000; Sievert et al., 2013). 
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O gênero Staphylococcus possui ampla associação às infecções 
oportunistas e está presente na microbiota anfibiôntica da pele e nas superfícies 
mucosas de humanos, principalmente da cavidade nasal, axilas, boca, vagina e 
intestino (Foster et al., 2014). São responsáveis por produzir diversos fatores de 
virulência, como toxinas, adesinas e componentes de evasão imunológica, que 
são importantes, principalmente, na interação do microrganismo com o hospedeiro 
durante o processo inicial de colonização (adesão e invasão), nos mecanismos de 
evasão (fuga) das defesas do hospedeiro e na modulação da resposta imune (Gill 
et al., 2005; Foster et al., 2014). Essa característica, somada à grande capacidade 
que possuem em formar biofilmes, resulta em uma estratégia fácil para a 
sobrevivência em ambiente hostil, tornando as células bacterianas menos 
acessíveis ao sistema de defesa do organismo e aos antimicrobianos (Stoodley & 
Stoodley, 2005). Essa situação acaba dificultando o tratamento de infecções 
hospitalares, principalmente aquelas oriundas de dispositivos médicos, e essa 
consequente falha na terapia bacteriana resulta na necessidade de substituição 
dos dispositivos, aumento do risco dos pacientes e seleção de bactérias 
resistentes aos antimicrobianos (Mónzon et al., 2002). 
Os microrganismos dificilmente são encontrados na forma livre no 
ambiente; para sobreviver diante das adversidades do ambiente eles crescem em 
comunidades denominadas biofilmes (Renner & Weibel, 2011). Os biofilmes 
podem ser definidos como comunidades complexas de microrganismos, aderidos 
em uma superfície e envoltos por uma matriz extracelular. A formação do biofilme 
envolve 4 passos principais: (1) adesão a superfície, (2) produção da matriz 
extracelular, (3) formação de microcolônias e intensificação da produção da matriz 
extracelular e (4) dispersão do biofilme (Renner & Weibel, 2011; Abdalla et al., 
2014). A produção da matriz extracelular é de extrema importância para o 
processo de maturação do biofilme, sendo composta por proteínas, ácidos 
nucléicos, lipídeos e principalmente por polissacarídeos. A matriz além de permitir 
que a adesão inicial dos microrganismos (passo 1) se torne irreversível, auxilia na 
estrutura do biofilme e acaba criando uma barreira contra estímulos mecânicos e 
4 
 
químicos, promovendo uma maior proteção contra o sistema imunológico e uma 
maior resistência a antimicrobianos (Renner & Weibel, 2011). 
Na busca de novos medicamentos antimicrobianos, uma alternativa 
interessante é a descoberta de novas funções ou a potencialização das atividades 
de medicamentos já conhecidos e amplamente utilizados (Fernandes et al., 1999). 
Este tipo de estratégia mostra-se claramente mais vantajosa tanto em termos de 
investimentos como em relação ao tempo de execução (Masunari & Tavares, 
2006). Nesse contexto, as estatinas aparecem com um grande potencial a ser 
explorado. Esse grupo de fármacos é amplamente prescrito na medicina, 
possuindo grande margem de segurança e baixa frequência de efeitos colaterais. 
Dessa forma, o presente estudo teve como objetivo avaliar o efeito das estatinas 
sobre o crescimento, viabilidade e formação de biofilme de espécies de 
microrganismos aeróbios patogênicos 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
5 
 
CAPÍTULO 1* 
Statins and antimicrobial effects: simvastatin as a potencial drug against 
Staphylococcus aureus biofilm. 
Graziano T.S.a 
Cuzullin M.C.a 
Franco G.C.b 
Schwartz-Filho H.O. c 
Andrade, E. D. a 
Groppo F.C.a 
Cogo K.a,c 
aPiracicaba Dental School, University of Campinas, Piracicaba, SP, Brazil 
bLaboratory of Physiology and Pathophysiology, Department of General Biology, State 
University of Ponta Grossa, PR, Brazil 
cDepartment of Dentistry, Implantology Area, University of Santo Amaro, São Paulo, SP,  
Brazil 
Corresponding author: 
Karina Cogo 
E-mail: karicogo@hotmail.com  
Department of Dentistry, Implantology Area, University of Santo Amaro 
Rua Prof. Eneas de Siqueira Neto, 340, 04829-300 São Paulo, SP, Brazil 
Phone/Fax: (11) 2141-8555  
Running title: Simvastatin and S. aureus biofilm 
Keywords: Statins, Staphylococcus aureus, Biofilms 
*submetido ao periódico Journal of Antimicrobial Chemoterapy (Anexo 1) 
6 
 
ABSTRACT 
Simvastatin is an important lipid-lowering agent, which belongs to the 
statins. These drugs have other effects called pleiotropic. Several studies have 
explored a possible protective effect of statins to reduce the morbidity and mortality 
of various infectious diseases. Staphylococcus aureus is considering one of the 
main pathogens of nosocomial infections; its high ability to form biofilms makes the 
treatment difficult. The present study evaluated the effects of simvastatin on the 
growth, viability and biofilm formation of S. aureus. The MIC of atorvastatin, 
pravastatin and simvastatin was evaluated against 10 strains of S. aureus, 
Pseudomonas aeruginosa, Escherichia coli and Enterococcus faecalis. As 
simvastatin showed activity against S. aureus, its effect on cell viability was 
addressed by time-kill and post-antibiotic effect assays. A possible synergistic 
effect between simvastatin and vancomycin was observed. In addition, the effect of 
simvastatin was evaluated against biofilms of S. aureus. The MIC of simvastatin 
against S. aureus were 15.65 µg/ml (ATCC 29213) and 31.25 µg/ml (ATCC 33591, 
43300, 14458 and 6538). The effect of simvastatin was bactericidal at 4x>MIC and 
bacteriostatic at MIC concentration. No synergistic effect was found between the 
simvastatin and vancomycin. However, the results obtained against S. aureus 
biofilms showed that, in addition to inhibiting biofilm formation, simvastatin was 
also able to act against mature biofilms, reducing cell viability and altering the 
production of polysaccharides. In conclusion, simvastatin has a great potential to 
be explored against S. aureus biofilm, especially in relation to the discovery of new 
antimicrobial agents. 
Key-words: Statins. Staphylococcus aureus. Biofilms. 
 
INTRODUCTION 
 
Simvastatin is a lipophilic drug that belongs to the group of statins. The 
statins are lipid-lowering agents that are involved in the reduction of cardiovascular 
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morbidity and mortality.1 These drugs exhibit a good margin of safety and 
tolerability with a low frequency of side effects, being the most commonly used 
agents for the reduction of lipids in patients with elevated cholesterol levels.2,3 All 
statins act via the same mechanism of action, as a competitive inhibitor of the 
enzyme 3-hydroxy-3-methyl-glutaryl-CoenzymeA reductase (HMG-CoA), 
decreasing the biosynthesis of cholesterol and increasing the removal of circulating 
Low-Density-Lipoprotein (LDL).4-6 
 Statins have effects other than lipid reduction, called pleiotropic 
effects,7 such as anti-inflammatory and immunomodulatory activities.8-10 Many 
studies have evaluated the effect of statins in the prevention, morbidity and 
mortality of various infectious diseases. Some of these studies showed that statins 
can prevent the establishment of infections or even reduce mortality rates in 
patients that take statins routinely.11-13  However, other studies did not find any 
protective effect of statins against infectious diseases.14 In patients with bacteremia 
and sepsis, the use of statins was associated with lower mortality in recent 
studies.15-17 Interestingly, some studies have also demonstrated an antimicrobial 
potential of statins against different bacterial species.18-21 For example, Simvastatin 
was able to inhibit host cell invasion18 and Staphylococcus aureus growth.19,20. In 
addition, Atorvastatin, Simvastatin and Rosuvastatin showed activity against 
several reference bacteria and clinical isolates.21 
 Pseudomonas aeruginosa, Staphylococcus epidermides, Enterobacter 
spp, Escherichia coli, Klebsiella spp, Acinetobacter spp and especially 
Staphylococcus aureus are frequently involved with nosocomial infections.22  S. 
aureus, one of the most important etiological agents of both nosocomial and 
community-onset infections,23 produces several virulence factors such as toxins, 
adhesins and components of immune evasion.24 These characteristics, combined 
with the ability that  this bacteria has to form biofilms results in an increase of 
survival in a hostile environment.25 The attached cell of biofilm produces an 
extracellular matrix composed of polysaccharides, proteins and DNA.26 This matrix 
8 
 
makes the bacterial cell less accessible to the defense system of the organism and 
antimicrobial agents, making the treatment of nosocomial infections difficult.26  
In the present study, we evaluated the activity of simvastatin, 
atorvastatin and pravastatin against a range of clinically important pathogens 
through susceptibility methods. We also tested if vancomycin and simvastatin, that 
was found to have antimicrobial activity, would act synergistically, by using a 
microtiter checkerboard method. We further evaluated the effects of simvastatin on 
S. aureus adhesion, biofilm viability and polysaccharides and protein production. 
These studies demonstrated that simvastatin has a significant activity against S. 
aureus biofilm.  
 
METHODS 
 
Chemicals and Experimental Groups 
 
Atorvastatin (atorvastatin calcium salt trihydrate), pravastatin 
(pravastatin sodium salt hydrate) and simvastatin (Sigma Chemical Co - Louis, 
MO, USA) were used for the experiments of Minimum Inhibitory Concentration 
(MIC). Atorvastatin and simvastatin were dissolved in 100% DMSO, while 
pravastatin was dissolved in distilled-deionised water. The final concentration of 
DMSO was 2.5%. Both gentamicin and vancomycin dissolved in deionized water 
were used as antimicrobial standards. 
The groups were: test group (culture medium + bacteria + statin or 
antimicrobial standard), positive control group (culture medium + bacteria) and 
vehicle control group (culture medium + bacteria + DMSO). Groups without 
inoculum but with any of the tested substances were considered as negative 
controls. All tests were performed using six replicates per group, in two separate 
occasions at least. 
 
Bacterial strains and Culture Conditions 
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The following strains were used:  Staphylococcus aureus ATCC 29213, 
S. aureus ATCC 6538, S. aureus ATCC 14458, S. aureus methicillin-resistant 
ATCC 33591, S. aureus methicillin-oxacillin-resistant ATCC 43300, Pseudomonas 
aeruginosa ATCC 27853, P. aeruginosa ATCC 25619, Escherichia coli ATCC 
25922, E. coli ATCC 10536, Enterococcus faecalis ATCC 29212. The bacterial 
were stored in TSB with 20% of glycerol at - 80 ºC. The strains were routinely 
cultured on TSA plates, in aerobic conditions, at 35 oC. 
The Muller Hinton Broth (MHB - Difco Co., Detroit, MI, USA) was used 
for the Minimum Inhibitory Concentration and planctonic tests. For biofilm 
experiments, the microorganism S. aureus ATCC 29213 was cultivated in Brain 
Heart Infusion (BHI - Difco Co., Detroit, MI, USA) with 1% D-glucose (Sigma 
Chemical Co - Poole, UK).  
For all the following tests, the bacterial inoculum was prepared in 0.9% 
NaCl considering an optical density of 0.1 at 660 nm, which was equivalent to 1-2 x 
108 CFU/ml. In each test, the amount of initial bacterial load was 5 x 105 CFU/ml.       
 
MIC 
 
MIC was determined by broth microdilution method as described by the 
Clinical and Laboratory Standards Institute (CLSI).27 The concentrations for all 
statins ranged from 250 to 0.24 µg/ml and for antimicrobial standards from 100 to 
0.06 μg /ml. Two-fold dilutions were made in 96-well plates with 100 µl of MHB per 
well. Then, the bacterial suspension (100 μl) was inoculated and the plates were 
incubated for 24 h at 35 oC. The lowest concentration with any visible bacterial 
growth was considered the MIC. In addition, bacterial growth was assessed by 
optical density measurement (660 nm). 
 
Time-kill assays 
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For all the following assays, vancomycin and simvastatin, which as the 
statin whit the best antimicrobial activity, were tested against S. aureus ATCC 
29213.  
The time kill assay was adapted from the method previously described 
by Eliopoulus & Moellering,28 and Raja et al.,29 MIC and 4x>MIC concentrations 
were chosen according to the data observed in the previous experiments. The time 
kill assay was performed as described in the MIC assay, and 25-μl samples were 
taken from the microtiter plates after 0, 2, 4, 8 and 12 h of incubation and spread 
on TSA plates. The viable colonies were counted after 24 h incubation to 
determine the CFU/ml. Killing curves were constructed by plotting the log10 CFU/ml 
versus time over 12 h. 
 
Post-antibiotic effect (PAE) 
 
The determination of post- antibiotic effect (PAE) was adapted from 
Craig & Gudmundsson,30 and Raja et al.,29 The concentrations used were 4x>MIC, 
2x>MIC, MIC and ½MIC. 24-well plates containing the tested substances were 
incubated for 2 h. The samples were centrifuged for 5 minutes at 1400 g, the 
supernatant was removed and new fresh medium was added. This procedure was 
repeated two times to ensure complete removal of drugs.  
The pellet was resuspended in culture medium, diluted 1:10 in tubes 
containing a final volume of 5 ml of culture medium and incubated at 35 °C. 
Samples of 25 µl were collected, before and after washing at every hour until 
visible growth (OD660nm = 0.3), and plated on TSA plates to obtain viable counts. 
The PAE was calculated using the following equation: PAE = T – C, where T is the 
time required for the initial bacterial culture increased by 1 log10CFU/ml from the 
removal of the antimicrobial, and C represents the time required for bacterial 
cultures not treated with antimicrobial to have an increase of 1 log10 CFU/ml. 
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Checkerboard Microdilution Assay 
 
In order to evaluate a possible interaction between simvastatin and 
vancomycin, a checkerboard microdilution assay as described by Odds et al.,31 
and Sun et al.,32 was used. Simvastatin and vancomycin were prepared at four 
times of the final concentration in separeted plates. Then, 50 µl simvastatin and 50 
µl of vancomycin were mixed and transfered to a new plate. Finnaly, 100 µl 
bacterial suspension was inoculated and the plates incubated in the same 
conditions. The analyses of results were based on the value of FICI ("fractional 
inhibitory concentration index") that was calculated using the following formula:  
∑FICI = FICIA + FICIB = MICAB/MICA + MICBA/MICB 
where MICA and MICB are the MICs of drugs A and B when acting alone 
and MICAB and MICBA are the MICs of drugs A and B when acting in combination, 
respectively.  
FICI values < 0.5 represent synergism in the interaction between drugs. 
FICI values between 0.5 < FICI < 4.0 are classified as indifferent and where FICI 
values are > 4.0, they are classified as antagonism. 
 
Biofilm formation assay 
 
The experiments of biofilm formation were carried out using U-bottom 
96-well plates. The concentrations for simvastatin and vancomycin ranged from 
1/28xMIC to 4x>MIC. This test was conducted similarly to the experiments of MIC, 
being the substances added at the beginning of biofilm formation (t=0).  
After 24 h the incubation, the plates were washed with distilled-
deionised water for removing dead or unattached cells. After drying at room 
temperature, the quantification of biofilm formed in each well was made by optical 
density (OD575nm) with 0.4% crystal violet solution and 100% ethanol.
33 
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Analysis of biofilm formation by scanning electron microscopy (SEM) 
 
The effect of simvastatin on biofilm formation was analyzed by SEM. 
The biofilm was formed as described in the previous item, with the following 
modifications. After growing for 24 h in Lab-Tek® Chambers (Nunc, Naperville, IL, 
USA), glutaraldehyde/PBS 3% (v / v, pH 7.4) were added for 12 h for fixation of 
samples. Then, the samples were dehydrated with ethanol (50% to 100%). The 
biofilms were coated with gold and examined with JEOL JSM5600LV (JEOL Ltd., 
Tokyo, Japan) scanning electron microscopy.34  
  
Biofilm viability assay 
 
To assess the effect of simvastatin on the viability of mature biofilm, 24 
h-biofilms were exposed to the antimicrobial drugs. Biofilms of S. aureus ATCC 
29213 were formed in cellulose acetate membranes filters (diameter: 25 mm; pore 
size: 0.2 µm; Sartorius AG, Germany) placed at the bottom of 6-well plates.  
After biofilm formation, the membranes were transferred to a new plate 
containing culture media and the antimicrobial substances at 4x>MIC. The plates 
were incubated for 24 h at 35 oC. The membranes were then washed three times 
with 0.9% NaCl and sonicated (Vibra Cell 400W, Sonics & Materials Inc., 
Newtown, CT, USA) with 5% range by 30 seconds for dispersion of the biofilm. 
Samples of 10 µl were collected, plated on TSA and kept at 35°C under for 24 h, 
when viable counts were then obtained.  
 
Quantification of polysaccharides, proteins and biomass 
 
In addition to viability of the biofilm, the production of polysaccharides, 
proteins and biomass (dry weight) after exposure to simvastatin was also analyzed.  
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The biofilms were formed in the membranes and sonicated as described 
previously. 800 µl were collected for the extraction of polysaccharides as described 
by Aires et al.35 and quantified by the phenolsulfuric method.36 The protein 
extraction was carried out using a 2M NaOH solution,37 and subsequently 
quantified by colorimetric assays through BCA protein quantification (Thermo 
scientific, Scottdale, AZ, USA). For biomass (dry weight), 1000 µl of each sample 
were centrifuged, and the pellet was dried in a lyophilizer (Lyo Chamber Guard 
Christ LCG 121505 PMMA (Nova Analítica) Alpha 2-4 LD plus) e then weighed. 
 
Statistics 
All tests were performed using six replicates per group, in two separate 
occasions at least. Data was analyzed by using GraphPad version 5.00 (San 
Diego, California, USA). The normality of data was tested by using Shapiro-Wilks 
test. Data with normal distribution were compared using an ANOVA, and significant 
differences between control and treatment groups were determined using the 
Bonferroni post-hoc test. Data abnormally distributed were analyzed by Kruskal-
Wallis and Dunn post-hoc tests. The significant level was set at 5%. 
 
RESULTS 
 
Simvastatin but not Atorvastatin and Pravastatin has antibacterial activity 
against S. aureus  
 
Simvastatin showed activity against all strains of S. aureus, but had no 
effect against the other species tested. The MIC values for simvastatin and the 
antimicrobial standards are shown in Table 1. No MICs for atorvastatin and 
pravastatin were observed at the concentrations tested. The concentrations of 
DMSO (2.5% V/V) used in all tests did not interfere with bacterial growth. The 
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strains S. aureus 29213, 33591, 14458, 43300 and 6538 and E. faecalis were 
sensitivity to vancomycin, while for gentamicin only S. aureus 43300 was resistant. 
All values of MIC for the antibiotics were in accordance to CLSI. 
 
Table1. Minimum Inhibitory Concentration (µg/ml) for simvastatin, gentamicin and 
vancomycin. 
Bacterial strains Simvastatin Gentamicin                                Vancomycin               
S. aureus 29213 15.65 0.78 1.56 
S. aureus 33591 
(MRSA) 
31.25 3.12 1.56 
S. aureus 14458 
(ORSA) 
31.25 0.78 1.56 
S. aureus 43300 31.25 ---- 1.56 
S. aureus 6538 31.25  1.56 1.56 
P. aeruginosa 27853 ---- 0.78 ---- 
P. aeruginosa 25619 ---- 0.39 ---- 
E. coli 25922 ---- 1.56 ---- 
E. coli 10536 ---- 0.78 ---- 
E. faecalis 29212 ----  6.25 3.12 
 
 
Statins effect on S. aureus strains are dose and drug dependent, as 
observed in Figure 1. Pravastatin also showed a reduction on S. aureus strains 
growth, but it did not completely inhibit these strains. Simvastatin effects against S. 
aureus were more prominent, even considering sub-MIC concentrations (p < 0.05).  
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Figure 1. Mean and standard deviation of optical density (660 nm) representing the bacterial growth 
of S. aureus when exposed to simvastatin and pravastatin. A. S. aureus 29213. B. S. aureus MRSA 
33591. C. S. aureus MRSA 43300. D. S. aureus 14458. E. S. aureus 6538. Significant differences 
between the treatment and the control group were considered when *p<0.05, **p<0.01 or 
***p<0.001 (2-way ANOVA, Bonferroni). 
 
 
A B C 
D E 
16 
 
Figure 2 shows the effect of simvastatin on S. aureus cell viability during 
12 h of exposure. Simvastatin at a concentration of 4x>MIC exhibited a bactericidal 
effect against S. aureus ATCC 29213, causing a reduction in the number of viable 
cells (Fig. 2A), while the MIC concentration showed a bacteriostatic effect (Fig. 
2B), since the number of cells remained constant during 12 h. Vancomycin showed 
a bactericidal effect for both concentrations studied. However, more time was 
required to kill 100% of cells for the lower concentration.  
Figure 2C shows the post-antibiotic effect (PAE) for both drugs. 
Vancomycin showed greater PAE than Simvastatin; however, no differences (p > 
0.05) between the PAE of the two drugs was observed at 4x>MIC. DMSO did not 
showed any effect in both time-kill and PAE assays. 
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Figure 2. A. Effect of simvastatin and vancomycin on cell viability during 12 h exposure, 
concentration equivalent to 4xMIC. B. Effect of simvastatin and vancomycin on cell viability during 
12 h exposure, concentration equivalent to MIC. C. Post-antibiotic effect of simvastatin and 
vancomycin. Significant differences between the treatment and the control group when *p<0.05 or 
***p<0.001 (ANOVA 2way). 
 
Simvastatin has no synergistic effect with Vancomycin 
 
FICI values were higher than 0.5 as shown in Table 2, indicating that 
there is no synergic effect between simvastatin and vancomycin against S. aureus. 
 
 
A B 
C 
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Table 2. FICI
1
 values for association between simvastatin and vancomycin. FICI < 0.5 = synergism. 
0.5 < FICI  < 4.0 = indifferent. FICI > 4.0 = antagonism. 
 
Bacterial strain FICI  
S. aureus 29213 0.56 
S. aureus 33591 1.06 
S. aureus 14458 1.00 
S. aureus 43300 1.06 
S. aureus 6538 1.03 
 
 
Simvastatin inhibits biofilm formation of S. aureus 
 
Figure 3A shows the absorbance values for simvastatin and 
antimicrobial standards. The concentrations tested ranged from 1/128 MIC to 4x 
MIC, thus the concentrations for each drug were: 0.12 - 62.6 µg/ml for simvastatin 
and 0.012 - 6.24 µg/ml for vancomycin.  
Simvastatin from 1/8 MIC up to 4x MIC (1.95 to 62.6 µg/ml) reduced 
significantly the biofilm formation (p < 0.05). Inhibition of biofilm was observed for 
the antimicrobial standard drug at 1/2MIC (0.78 µg/ml). When analyzed by MIC 
range, simvastatin could reduce biofilm formation more significantly until the 
concentration 1/64 MIC when compared to vancomycin (p < 0.005). DMSO did not 
alter S. aureus ATCC 29213 biofilm formation (p > 0.05). The images obtained by 
SEM confirmed the inhibitory effect of Simvastatin on S. aureus 29213 biofilm 
(Figure 3B).  
 
 
 
1
 FICI: fractional inhibitory concentration index 
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Figure 3. A. Mean and standard deviation of absorbance (OD575nm) representing the biofilm 
formation of S. aureus 29213 in the presence of simvastatin e vancomycin. Different letters 
represent statistical difference; comparisons were made at each dilution and the control group 
(Kruskal-Wallis). B. Images obtained by SEM representing the biofilm formation of S. aureus 29213 
in the presence of Simvastatin. In column 1 are the 4x MIC, 2X MIC and MIC concentrations, 
respectively. In column 2 are the concentration ½ MIC, vehicle group (DMSO) and the control 
group, respectively. 
 
Simvastatin decreases cell viability and alters the production of 
polysaccharides in mature biofilms 
 
A B 
1 2 
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The cell viability of S. aureus 29213 after treatment with simvastatin and 
vancomycin is  exposed in Figure 4. The results showed that simvastatin (4x MIC = 
62.6 µg/ml) could reduce significantly viable cells of biofilm when compared to the 
control and vehicle group (p<0.005), while vancomycin (4x MIC = 6.24 µg/ml) 
showed no difference when compared to group control (p > 0.05). DMSO did not 
reduce the number of viable cells. Thus, simvastatin was effective against mature 
biofilm of S. aureus 29213, and despite the concentrations of the statin and 
antibiotic are different, the proportion in relation to the MIC was the same for all 
drugs. 
 
Figure 4. Mean and standard deviation of CFU/ml representing the cell viability of S. aureus 29213 
biofilm after exposed to simvastatin and vancomycin. Significant differences between the treatment 
and the control group when **p < 0.01 (Kruskal-Wallis). 
 
 
As simvastatin inhibited S. aureus ATCC 29213 biofilms, it is possible 
that this statin interfered in the extracellular matrix of biofilm. The production of 
extracellular polysaccharide soluble (EPS) was very low (data not shown). The 
results for extracellular polysaccharide insoluble (EPSI) and intracellular 
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polysaccharide (IPS) are both shown in Table 3. Simvastatin reduced the 
production of EPSI (p < 0.05) and increased the production of IPS when compared 
with control (p < 0.05). However, simvastatin did not change the total proteins 
production (p > 0.05). DMSO did not alter the amounts of polysaccharides, proteins 
and biomass. 
 
 
Table 3. Effects of simvastatin on the production of polysaccharides, proteins and biomass of S. 
aureus biofilm. 
2 
 Polysaccharides (µg/mg dry weight) Proteins 
(µg/mg dry 
weight) 
Biomass  
(mg) EPSI IPS 
Simvastatin 22.7 ± 9.0
*
 78.6 ± 25.4
*
 2.3 ± 0.4 0.66 ± 0.12
*
 
Control  40.7 ± 9.6 34.1 ± 8.6 1.9 ± 0.4 0.93 ± 0.13 
 
 
DISCUSSION 
 
The potential of pleiotropic effects exhibited by statins conducted a 
series of studies to investigate the role of these drugs in the development of 
infections.15-17,38,39 The antimicrobial activity of these drugs was proposed and 
investigated by some authors.18-21 We evaluated the antimicrobial activity of 
atorvastatin, pravastatin and simvastatin against 10 bacterial strains associated 
with nosocomial infections. In addition, as simvastatin showed activity against S. 
 
2
 The values of polysaccharides and proteins were normalized by dry weight. Significant differences 
between the treatment and the control group when *p < 0.05 (Kruskal-wallis). 
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 aureus, to obtain more information on antibacterial activity of this drug, we 
explored its effects on planktonic cells and biofilm of S. aureus 29213. 
In our study, simvastatin showed 100% of inhibition only against S. 
aureus. In addition, sub-MIC concentrations were able to reduce the growth of S. 
aureus even at concentrations lower than MIC (0.24 µg/ml). The MICs found in the 
present study were lower than the MICs showed previously in other studies 
considering S. aureus,20 and other bacterial species.21 However, the values found 
for antimicrobial standards are in accordance to CLSI,27 demonstrating that the 
method used in our study was suitable. Finally, Bergman et al.,19 found a MIC 
value of 15.6 µg/ml for simvastatin against Streptococcus pneumoniae, which is a 
concentration very close to the ones found in the present study. 
Atorvastatin and pravastatin did not present full inhibitory activity, as 
demonstrated by the MIC tests. However, pravastatin, and also simvastatin were 
able to reduce the growth of S. aureus, E. coli, P. aeruginosa and E. faecalis (data 
not shown). Masadeh et al.,21 reported inhibitory activity for simvastatin and 
atorvastatin against several species, including E. coli, P. aeruginosa and E. 
faecalis. The enhanced antimicrobial activity of simvastatin in comparison to 
pravastatin and atorvastatin may be related to differences in their chemical 
characteristics, as described previously.20,21  
Pravastatin and simvastatin are semi-synthetic forms, derivatives of 
lovastatin, a metabolic product of Penicillium citrinum,40 being atorvastatin the total 
synthetic form.2 Simvastatin and atorvastatin are lipophilic, while pravastatin has 
hydrophilic properties.41 Thus, simvastatin probably cross the cell membrane more 
easily, causing bacterial inhibition in a dose dependent manner. Although lipophilic, 
atorvastatin has no significant antimicrobial activity. This molecule is not derived 
from a fungal metabolite, and these would be the reason for lacking antimicrobial 
effects. However, further studies on structure-activity relationship should be carried 
out to better understand the antimicrobial properties of statins.   
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To better understand the antimicrobial properties of statins, we 
investigated its effects on S. aureus 29213 in planktonic and biofilm assays, since 
this strain has a better ability to form biofilm when compared with resistant strains. 
We first evaluated the cell viability when S. aureus 29213 was exposed to 
simvastatin for 2, 4, 8 and 12 (time kill assays). At 4x MIC, simvastatin reduced the 
number of viable cells, especially after 12 h of exposure.But, at MIC concentration, 
the number of viable cells remained constant during all periods of exposure. . 
Thus, while the 4x MIC killed S. aureus 29213, the MIC only inhibited the growth, 
thus demonstrating that the type of effect exhibited by simvastatin, bactericidal or 
bacteriostatic, is dose-dependent. However, vancomycin showed a bactericidal 
effect for both concentrations, reducing the number of viable cells more 
significantly than simvastatin. In addition, we also verified how long these effects 
persist after the removal of the drug, also known as post-antibiotic effect (PAE). 
For concentration 4x MIC, simvastatin and vancomycin showed a similar PAE. This 
find emphasizes that the effect is due to prior antimicrobial properties rather than to 
persisting sub-inhibitory concentrations.  
The ability of simvastatin to produce PAE similarly to vancomycin is an 
interesting finding, as theoretically it could suppress bacterial growth even when 
concentrations fall below the MIC.30  
Previous studies reported in vitro synergistic and antagonistic effects of 
the association among statins and antifungals.42-44 Therefore, we investigated a 
possible interaction between simvastatin and vancomycin by checkerboard test. 
However, the combination of these drugs had no synergistic effect against any 
strain of S. aureus. The FICI value found for S. aureus 29213 was low compared to 
the other strains, but more studies are needed to verify if this interaction has some 
potential. 
Despite the importance of determining the MIC and the antibacterial 
activity against planktonic cells, microorganisms are not usually found in body-
liquids.45 To face the adversities of the environment, microorganisms adhere on 
surfaces and grow grouped involved by extracellular polymeric substances (EPS), 
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forming communities known as biofilms.45,46 Biofilm formation involves four steps: 
(1) reversible adhesion to a surface, (2) production of EPS (irreversible adhesion), 
(3) microcolonies formation and intense production of EPS and (4) biofilm 
dispersion.46,47  
Our results show that simvastatin was able to inhibit biofilm formation in 
concentrations lower than the MIC (8x < MIC). This inhibition was confirmed by 
images obtained by scanning electron microscopy (SEM). Considering both vehicle 
and control groups, it was possible to observe a biofilm in a mature stage, with the 
cells immersed in an extracellular matrix. In the presence of simvastatin, however, 
few cells are adhered on the surface considering drug-concentrations equal or 
higher than MIC. For concentration ½ MIC, more cells were adhered, but biofilm 
failed to develop and achieve step 3. Thereby, simvastatin inhibits biofilm formation 
by S. aureus, probably preventing adherence of cell in concentrations higher than 
MIC and the development of biofilm in sub-MIC concentrations. 
To fight mature biofilms has become a challenge. They are more 
resistant to antimicrobial agents, which difficult the treatment, leading to 
complications for the patient.48 We investigated the effect of simvastatin against S. 
aureus biofilms with 24 h of growth, in an more advanced stage of maturation. 
Simvastatin exhibited excellent activity in concentrations at 4x MIC, reducing the 
cell viability at 10x, while vancomycin exhibited no effects. The concentration of 
antibiotic required to kill cells in biofilm is much higher than to kill planktonic cells, 
sometimes 100 or 1000 times the MIC.49 Therefore, our findings revealed a 
potential of simvastatin to be explored, since in concentrations only 4 times the 
MIC they have had an excellent ability to decrease cell viability. Unfortunately, the 
difficult dilution of simvastatin did not allow testing higher concentrations. 
Several mechanisms explaining the resistant of biofilms have been 
described.48,49 The extracellular matrix is implicated as an important mechanism, 
especially by decreasing the penetration of an antibiotic.49 We hypothesized that 
effect of simvastatin could also involve an effect on two important components of 
EPS, polysaccharides and proteins. The EPSI contribute to structure, being 
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responsible for integrity of biofilms.45,50 Some EPSI are also associated with 
resistance in bacterial biofilms, as the Poly-(1,6)-N-acetyl-D-glucosamine (PNAG), 
the major extracellular polysaccharide in S. aureus, is responsible for preventing 
fluid convection and the transport of solute through biofilms.51 After treatment with 
simvastatin, the biofilm showed a reduction in the production of EPSI and an 
increase in the production of IPS, when compared to the control group. The 
increase in production of IPS in some bacteria such as S. mutans is associated to 
a nutrition reservoir allowing to extent the survival in limiting conditions.52 A 
possible hypothesis for this finding would be that in attempt to increase its survival 
in presence of simvastatin, S. aureus decreases the production of EPSI to produce 
reserve polysaccharides. This change could also explain the excellent effect of 
simvastatin on the S. aureus viability.  
Since EPSI is responsible for biofilm structure and it is a major 
component of the extracellular matrix, a reduction in its production could lead 
biofilms more accessible to drugs. However, more studies are needed to 
understand the role of simvastatin in the production of polysaccharides. 
Simvastatin did not alter significantly the amount of proteins. The 
production of proteins is generally more intense during biofilm formation, having a 
key role in the colonization of biofilm.50 Thus, the absence of effect on the protein 
production is understandable. Perhaps a qualitative study can better respond if 
simvastatin has some effect on the production of proteins. The reduction in 
biomass of biofilm is probably due to reduction of the polysaccharides, since they 
are the major fraction of the EPS.45 
The concentrations found to have antimicrobial properties are a 
thousand times higher than the plasmatic concentrations raised in patients under 
statins therapy.19 However, regardless of whether the physiological concentrations 
of simvastatin present or not bacterial activity, our results highlight an antimicrobial 
potential to be explored. Our study was the first to investigate the effect of 
simvastatin on bacterial biofilms, showing a great antimicrobial activity for this 
statin. The identification and development of new antibiotics, especially those with 
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new mechanism of action, are of most importance in public health worldwide.53 We 
believe that studies on its molecular structure would bring a new antibacterial 
pharmacophore, which would be useful in the future as a template to the 
development of new antibiotics.   
In conclusion, simvastatin has antimicrobial activity against S. aureus 
biofilm, reducing its formation, viability and polysaccharides production. These 
findings can contribute to the search for new antibacterial drugs, considering the 
potential of simvastatin as an antibiotic prototype.  
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CONCLUSÃO 
 
Os resultados demonstram que a sinvastatina apresentou atividade 
contra S. aureus, sendo capaz de impedir a formação de biofilme, e agir contra 
biofilmes já formados, diminuindo a viabilidade celular e alterando a produção de 
polissacarídeos. Em conclusão, essa droga apresentou um excelente potencial a 
ser explorado para obtenção de novos antimicrobianos. 
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